Intellia Therapeutics has reported positive Phase 3 results for lonvoguran [...]
Pharvaris has secured approximately $175 million through a public offering [...]
Intellia Therapeutics has reported positive Phase 3 results for lonvoguran [...]
Pharvaris has secured approximately $175 million through a public offering [...]